| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dexiao Zhu, Jian Zhang, Xiaokuang Ma, Mei Hu, Fei Gao, Jack B Hashem, Jianlu Lyu, Jing Wei, Yuehua Cui, Shenfeng Qiu, Chu Che. Overabundant endocannabinoids in neurons are detrimental to cognitive function. bioRxiv : the preprint server for biology. 2024-09-30. PMID:39345517. |
previous studies have demonstrated that inactivating monoacylglycerol lipase (magl), the primary enzyme responsible for degrading 2-ag in the brain, alleviates neuropathology and prevents synaptic and cognitive decline in animal models of neurodegenerative diseases. |
2024-09-30 |
2024-10-02 |
mouse |
| Gerard Ross. Novel Pyrazolopyridine Inhibitors of Monoacylglycerol Lipase for the Treatment of Neurodegenerative Diseases and Neuroinflammation. ACS medicinal chemistry letters. vol 15. issue 1. 2024-01-17. PMID:38229740. |
novel pyrazolopyridine inhibitors of monoacylglycerol lipase for the treatment of neurodegenerative diseases and neuroinflammation. |
2024-01-17 |
2024-01-19 |
Not clear |
| Dexiao Zhu, Jian Zhang, Jack Hashem, Fei Gao, Chu Che. Inhibition of 2-arachidonoylglycerol degradation enhances glial immunity by single-cell transcriptomic analysis. Journal of neuroinflammation. vol 20. issue 1. 2023-01-31. PMID:36717883. |
inhibition of 2-ag metabolism by inactivation of monoacylglycerol lipase (magl), the primary enzyme that degrades 2-ag in the brain, produces anti-inflammatory and neuroprotective effects in neurodegenerative diseases. |
2023-01-31 |
2023-08-14 |
Not clear |
| Dexiao Zhu, Jian Zhang, Fei Gao, Mei Hu, Jack Hashem, Chu Che. Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. Experimental neurology. 2022-12-08. PMID:36481187. |
inhibition of 2-ag degradation by inactivation of monoacylglycerol lipase (magl), a key enzyme degrading 2-ag in the brain, alleviates neuropathology and improves synaptic and cognitive functions in animal models of neurodegenerative diseases. |
2022-12-08 |
2023-08-14 |
Not clear |
| Anca Zanfirescu, Anca Ungurianu, Dragos Paul Mihai, Denise Radulescu, George Mihai Nitulesc. Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases. Molecules (Basel, Switzerland). vol 26. issue 18. 2021-11-11. PMID:34577139. |
targeting monoacylglycerol lipase in pursuit of therapies for neurological and neurodegenerative diseases. |
2021-11-11 |
2023-08-13 |
Not clear |
| Estefania Rojo-Bustamante, Ignacio Íñigo-Marco, Miguel Angel Abellanas, Rodrigo Vinueza-Gavilanes, Ana Baltanás, Esther Luquin, Montserrat Arrasate, Maria S Aymeric. CB2 Receptors and Neuron-Glia Interactions Modulate Neurotoxicity Generated by MAGL Inhibition. Biomolecules. vol 10. issue 8. 2021-06-14. PMID:32824740. |
monoacylglycerol lipase inhibition (magl) has emerged as an interesting therapeutic target for neurodegenerative disease treatment due to its ability to modulate the endocannabinoid system and to prevent the production of proinflammatory mediators. |
2021-06-14 |
2023-08-13 |
rat |
| Zhen Chen, Wakana Mori, Hualong Fu, Michael A Schafroth, Akiko Hatori, Tuo Shao, Genwei Zhang, Richard S Van, Yiding Zhang, Kuan Hu, Masayuki Fujinaga, Lu Wang, Vasily Belov, Daisuke Ogasawara, Pilar Giffenig, Xiaoyun Deng, Jian Rong, Qingzhen Yu, Xiaofei Zhang, Mikhail I Papisov, Yihan Shao, Thomas L Collier, Jun-An Ma, Benjamin F Cravatt, Lee Josephson, Ming-Rong Zhang, Steven H Lian. Design, Synthesis, and Evaluation of Journal of medicinal chemistry. vol 62. issue 19. 2020-06-15. PMID:31518130. |
design, synthesis, and evaluation of dysfunction of monoacylglycerol lipase (magl) is associated with several psychopathological disorders, including drug addiction and neurodegenerative diseases. |
2020-06-15 |
2023-08-13 |
Not clear |
| Ming Jiang, Mario van der Stel. Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders. Journal of medicinal chemistry. vol 61. issue 20. 2019-09-30. PMID:30354159. |
monoacylglycerol lipase (mgll or magl) is a critical point of regulation of both endocannabinoid and eicosanoid signaling pathways in the brain, thereby providing novel therapeutic opportunities for neurological and neurodegenerative diseases. |
2019-09-30 |
2023-08-13 |
Not clear |
| Giulio Poli, Margherita Lapillo, Vibhu Jha, Nayla Mouawad, Isabella Caligiuri, Marco Macchia, Filippo Minutolo, Flavio Rizzolio, Tiziano Tuccinardi, Carlotta Granch. Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. Journal of enzyme inhibition and medicinal chemistry. vol 34. issue 1. 2019-03-06. PMID:30696302. |
monoacylglycerol lipase (magl) is an attractive therapeutic target for many pathologies, including neurodegenerative diseases, cancer as well as chronic pain and inflammatory pathologies. |
2019-03-06 |
2023-08-13 |
Not clear |